Cullinan Therapeutics Presents New Data on CLN-049 at ASH Meeting
Meno di 1 minuto di lettura
On November 3, 2025, Cullinan Therapeutics announced promising clinical data for CLN-049 in AML and MDS patients.
Key Highlights:
- CLN-049 showed anti-leukemic activity with a 31% CRc rate at 12 μg/kg.
- Overall response rate reached 69% at the highest dose level.
- Responses observed regardless of genetic risk, including TP53 mutations.
- Manageable safety profile with common TEAEs like CRS and infusion reactions.
- Data to be presented at the ASH Annual Meeting in December 2025.
Original SEC Filing: Cullinan Therapeutics, Inc. [ CGEM ] - 8-K - Nov. 03, 2025
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.